| Effects of teriparatide retreatment in osteoporotic men and women. | |
| | |
MedLine Citation:
|
PMID: 19401368 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: The stimulatory effect of teriparatide on bone mineral density (BMD) and bone turnover is initially exuberant, but then diminishes. OBJECTIVE: Our objective was to determine whether retreating with teriparatide after a drug-free period can restore the initial exuberant response to teriparatide. DESIGN AND SETTING: This was a planned extension of a randomized controlled trial conducted in a single university hospital. PATIENTS AND INTERVENTION: Subjects previously participated in a 30-month randomized trial comparing the effects of alendronate (group 1), teriparatide (group 2), or both (group 3) on BMD and bone turnover in men and women with low BMD (phase 1). Subjects who completed phase 1 on their assigned therapy entered phase 2 (months 30-42), during which teriparatide was stopped in groups 2 and 3. Teriparatide was administered to all subjects during months 42 to 54 (phase 3). MAIN OUTCOME MEASURES: We compared changes in BMD and markers of bone turnover (serum osteocalcin, N-terminal propeptide of type 1 collagen, and N-telopeptide) between phase 1 and 3 in subjects receiving teriparatide alone. RESULTS: Posterior-anterior and lateral spine BMD increased 12.5 +/- 1.5 and 16.9 +/- 1.7%, respectively, during the first 12 months of teriparatide administration and 5.2 +/- 0.8 and 6.2 +/- 1.8%, respectively, during teriparatide retreatment (P < 0.001 and P = 0.001). Increases in osteocalcin (P < 0.001), N-terminal propeptide of type 1 collagen (P < 0.001), and N-telopeptide (P < 0.001) were greater during the first period of teriparatide administration. CONCLUSION: The response to teriparatide is attenuated when readministered after a 12-month hiatus. |
| | |
Authors:
|
Joel S Finkelstein; Jason J Wyland; Benjamin Z Leder; Sherri-Ann M Burnett-Bowie; Hang Lee; Harald Jüppner; Robert M Neer |
Related Documents
:
|
20400258 - Patient education in groups increases knowledge of osteoporosis and adherence to treatm... 16687238 - Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. 18581668 - Does standing protect bone density in patients with chronic spinal cord injury? 19816648 - Comparison of monthly ibandronate versus weekly risedronate in preference, convenience,... 22338468 - Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after car... 635488 - Urinary infection and transurethral prostatectomy. |
Publication Detail:
|
Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural Date: 2009-04-28 |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 94 ISSN: 1945-7197 ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-07-08 Completed Date: 2009-08-06 Revised Date: 2010-09-27 |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 2495-501 Citation Subset: AIM; IM |
Affiliation:
|
Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. jfinkelstein@partners.org |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00000400 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Alendronate / administration & dosage, adverse effects Algorithms Bone Density / drug effects Bone Density Conservation Agents / administration & dosage, adverse effects, therapeutic use Dose-Response Relationship, Drug Drug Combinations Female Humans Male Medication Adherence Middle Aged Osteoporosis / drug therapy* Retreatment Teriparatide / administration & dosage, adverse effects, therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
5 P50 AR44855/AR/NIAMS NIH HHS; K24 DK02759/DK/NIDDK NIH HHS; RR-1066/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Drug Combinations; 52232-67-4/Teriparatide; 66376-36-1/Alendronate |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hypothyroidism secondary to hypothalamic-pituitary dysfunction may be part of the phenotype in kline...
Next Document: Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experie...